2Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N Engl J Med,2002,346(6) :393-403.
3Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA,2003,290(4) :486-494.
4Hanefeld M, Koehler C, Henkel E, et al. Post-challenge hyperglycemia relates more strongly than fasting hyperglycemia with carotid intimae-media thickness: the RIAD study. Diabet Med, 2000, 17(12) :212-218.
5DECOOE Study Group. The European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality:comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med,2001,161( 3 ) :397-405.
6Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose tolerant individuals with a first-degree NIDDM relative. JAMA, 1995,273 (23): 1855-1861.
7Luo M, Xiujun L, Li J, et al. Study on insulin receptor content and distribution of islet α-cell in diabetic rats-prelimary insight into the mechanism of pancreasticd-cell insulin resistance. Diabetes, 2004,53 (suppl 2) :A313.
8Broenlee M. The pathobiology of diabetic complication:a unifying mechanism. Diabetes,2004,53 (suppl 2) :6.
9The expert committee on the diagnosis and classification of diabetes mellitus:follow-up report on the diagnosis of diabetes mellitus. Diabetes Care,2003,26( 11 ) :3160-3167.
